Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Kiarash Riazi, Hassan Azhari, Jacob H Charette, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 851-861
Closed Access | Times Cited: 1257

Showing 26-50 of 1257 citing articles:

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 47
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
Stephen A. Harrison, Carole Thang, Sébastien Bolze, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 914-925
Closed Access | Times Cited: 46
The Influence of Sex Hormones in Liver Function and Disease
Alvile Kasarinaite, Matthew C. Sinton, Philippa T. K. Saunders, et al.
Cells (2023) Vol. 12, Iss. 12, pp. 1604-1604
Open Access | Times Cited: 45
The Link between NAFLD and Metabolic Syndrome
Fabiana Radu, Claudia-Gabriela Potcovaru, Teodor Salmen, et al.
Diagnostics (2023) Vol. 13, Iss. 4, pp. 614-614
Open Access | Times Cited: 43
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 2, pp. 180-200
Open Access | Times Cited: 43
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Pegah Golabi, James M. Paik, Ameeta Ravi Kumar, et al.
Metabolism (2023) Vol. 146, pp. 155642-155642
Closed Access | Times Cited: 43
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma
Riccardo Nevola, Giovanni Tortorella, Valerio Rosato, et al.
Biology (2023) Vol. 12, Iss. 7, pp. 984-984
Open Access | Times Cited: 42
The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis
Marc Schoeler, Sandrine Ellero‐Simatos, Till Birkner, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 40
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Tracey G. Simon, Robert M. Wilechansky, Stefania Stoyanova, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 920-920
Open Access | Times Cited: 37
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1071-1087
Closed Access | Times Cited: 31
Non-invasive testing and risk-stratification in patients with MASLD
Mirko Zoncapè, Antonio Liguori, Emmanuel Tsochatzis
European Journal of Internal Medicine (2024) Vol. 122, pp. 11-19
Closed Access | Times Cited: 30
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Axel Wester, Ying Shang, Emilie Toresson Grip, et al.
Gut (2024), pp. gutjnl-330962
Open Access | Times Cited: 30
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
Farah Abdelhameed, Chris Kite, Lukasz Lagojda, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 3, pp. 510-531
Open Access | Times Cited: 30
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 27
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 25
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
Limin Cao, Yu An, Huiyuan Liu, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 23
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 22
Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis
Patrik Nasr, Axel Wester, Mattias Ekstedt, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 5, pp. 1048-1057.e2
Open Access | Times Cited: 21
Acquisition of epithelial plasticity in human chronic liver disease
Christopher Gribben, Vasileios Galanakis, Alexander Calderwood, et al.
Nature (2024) Vol. 630, Iss. 8015, pp. 166-173
Open Access | Times Cited: 21
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa
Zobair M. Younossi, Pegah Golabi, James M. Paik, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 1061-1070
Closed Access | Times Cited: 20
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 20
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
Philip N. Newsome, Arun J. Sanyal, Kristiane Aasen Engebretsen, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 11-12, pp. 1525-1533
Open Access | Times Cited: 20
Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes
Ying Shang, Emilie Toresson Grip, Angelo Modica, et al.
Diabetes Care (2024) Vol. 47, Iss. 6, pp. 978-985
Open Access | Times Cited: 19

Scroll to top